Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes
Open Access
- 1 January 2013
- journal article
- review article
- Published by Informa UK Limited in Diabetes, Metabolic Syndrome and Obesity
- Vol. 6, 1-9
- https://doi.org/10.2147/dmso.s23166
Abstract
Abstract: The first dipeptidyl-peptidase-IV (DPP-4) inhibitor for the treatment of type 2 diabetes became available in 2006. Since then, the number of DPP-4 inhibitors has increased and DPP-4 inhibitors have developed into an important drug class. DPP-4 inhibitors act by increasing endogenous GLP-1 and GIP concentrations. Via this mechanism, insulin secretion is glucose-dependently stimulated and glucagon secretion inhibited. This results in a low risk for hypoglycemia. Furthermore, DPP-4 inhibitors are weight-neutral. Linagliptin is a novel DPP-4 inhibitor that, in contrast to the other members of this drug class, is eliminated by a biliary/hepatic route rather than by renal elimination. This property allows the use of linagliptin in type 2 diabetic patients with normal kidney function as well as in patients with renal insufficiency without dose adjustments. In comparative clinical studies, linagliptin was noninferior to other established antidiabetic agents, especially to metformin and sulfonylurea. It showed a superior safety profile over glimepiride regarding hypoglycemia, weight gain, a composite cardiovascular endpoint, and stroke. This review gives an overview on the efficacy and safety of linagliptin in comparison to the classical oral antidiabetic drugs as well as to the other DPP-4 inhibitors.Keywords
This publication has 42 references indexed in Scilit:
- 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trialThe Lancet, 2012
- Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)Diabetologia, 2012
- Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double‐blind, placebo‐controlled studyDiabetes, Obesity and Metabolism, 2012
- Linagliptin–-A Novel Dipeptidyl Peptidase Inhibitor for Type 2 Diabetes TherapyClinical Medicine Insights: Endocrinology and Diabetes, 2012
- Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trialDiabetes, Obesity and Metabolism, 2010
- Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?Trends in Pharmacological Sciences, 2009
- Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humansJournal of Pharmacy and Pharmacology, 2009
- (R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a Novel Xanthine-Based Dipeptidyl Peptidase 4 Inhibitor, Has a Superior Potency and Longer Duration of Action Compared with Other Dipeptidyl Peptidase-4 InhibitorsJournal of Pharmacology and Experimental Therapeutics, 2008
- The Absolute Oral Bioavailability and??Population-Based Pharmacokinetic Modelling of a Novel Dipeptidylpeptidase-IV Inhibitor, Vildagliptin, in Healthy VolunteersClinical Pharmacokinetics, 2007
- Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptidesRegulatory Peptides, 1999